NEW YORK, NY / ACCESSWIRE / August 13, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
TUFN Shareholders Click Here: https://www.zlk.com/pslra-1/tufin-software-technologies-ltd-loss-form?prid=8552&wire=1
CEMI Shareholders Click Here: https://www.zlk.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?prid=8552&wire=1
JCOM Shareholders Click Here: https://www.zlk.com/pslra-1/j2-global-inc-loss-submission-form?prid=8552&wire=1
* ADDITIONAL INFORMATION BELOW *
Tufin Software Technologies Ltd. (NYSE:TUFN)
Affected investors purchased TUFN securities pursuant and/or traceable to documents issued in connection with the Company's April 2019 initial public offering and/or its December 2019 secondary public offering.
Lead Plaintiff Deadline: September 21, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tufin-software-technologies-ltd-loss-form?prid=8552&wire=1
According to the filed complaint, (i) Tufin's customer relationships and growth metrics were overstated, particularly with respect to North America; (ii) Tufin's business was deteriorating, primarily in North America; (iii) as a result, Tufin's representations regarding its sustainable financial prospects were overly optimistic; and (iv) as a result, the documents issued in connection with the Company's initial public offering were materially false and/or misleading and failed to state information required to be stated therein.
Chembio Diagnostics, Inc. (NASDAQ:CEMI)
CEMI Lawsuit on behalf of: investors who purchased March 12, 2020 - June 16, 2020
Lead Plaintiff Deadline: August 17, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?prid=8552&wire=1
According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.
J2 Global, Inc. (NASDAQ:JCOM)
JCOM Lawsuit on behalf of: investors who purchased October 5, 2015 - June 29, 2020
Lead Plaintiff Deadline: September 8, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/j2-global-inc-loss-submission-form?prid=8552&wire=1
According to the filed complaint, during the class period, J2 Global, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) J2 Global engaged in undisclosed related party transactions; (2) J2 Global used misleading accounting to hide requisite impairments and underperformance in acquisitions; (3) several so-called independent members of the Company' board of directors and audit committee were not disinterested; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: